Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment
Conclusions: Significant within-group improvement in OAB-q symptom bother was noted in both the intravaginal estradiol and tolterodine groups for OAB symptoms, with no difference between groups. Greater improvement from 12-week single therapy to 24 and 52 weeks of combined therapy was noted in the group originally assigned to intravaginal estradiol. The role of combined medical therapy for OAB symptoms needs further investigation.
Source: Journal of Pelvic Medicine and Surgery - Category: Surgery Tags: Original Articles Source Type: research
More News: Alternative and Complementary Therapies | Detrol | Estradiol | Health | Incontinence | Overactive Bladder | Overactive Bladder Syndrome | Study | Surgery | Women